Indivior Pharmaceuticals Inc. reported second-quarter 2026 adjusted earnings of $1.15 per share, up 125.5% year over year and beating the Zacks Consensus Estimate of 97 cents, while total revenues rose 13.6% to $343 million, also surpassing expectations. The company raised its full-year 2026 net revenue guidance to $1.295-$1.365 billion from $1.215-$1.285 billion, and lifted its total Sublocade net revenue forecast to $1.01-$1.05 billion from $950-$990 million, reflecting stronger-than-expected commercial performance. Adjusted EBITDA for the quarter surged 111% to $186 million, and the company repurchased about 4.7 million shares for $175 million at an average price of $37.52. Shares have declined 5.3% since the earnings report, underperforming the S&P 500, but the stock holds a Zacks Rank #2 (Buy) with upward estimate revisions.
Indivior PLC Ordinary SharesQ2 earnings and revenue beat estimates, raised 2026 guidance, and strong Sublocade performance.
Ionis Pharmaceuticals Inc